GID4: A Potential Drug Target Or Biomarker (G79018)

Target Name: GID4

NCBI ID: G79018

GID4

GID4: A Potential Drug Target Or Biomarker

GID4 (GID4_HUMAN) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. GID4 is a non-coding RNA molecule that has been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

The GID4 gene has four known splice variants, GID4A, GID4B, GID4AB, and GID4AC, which have been shown to differ in their levels of expression and stability. GID4A and GID4B are predominantly expressed in the brain, while GID4AB and GID4AC are expressed in the liver and other tissues.

GID4 has been shown to be involved in the regulation of cellular processes that are important for brain development and function. For example, GID4 has been shown to play a role in the regulation of neuron survival and differentiation, as well as the regulation of neurotransmitter release.

In addition to its role in brain development and function, GID4 has also been shown to be involved in the regulation of cellular responses to stress and environmental stimuli. For example, GID4 has been shown to play a role in the regulation of cell death in response to stress, and has been shown to be involved in the regulation of inflammation in response to environmental stimuli.

GID4 has also been shown to be involved in the regulation of cellular interactions with other molecules, including its interactions with the protein PDGF-BB. PDGF-BB is a potent regulator of cell growth and differentiation, and has been shown to play a role in the development and progression of various diseases, including cancer. GID4 has been shown to interact with PDGF-BB and to regulate its activity, which may have implications for the regulation of cellular processes that are important for cancer development and progression.

GID4 has also been shown to be involved in the regulation of gene expression in various tissues and organs. For example, GID4 has been shown to play a role in the regulation of gene expression in the liver, where it has been shown to be involved in the regulation of the expression of genes involved in metabolism, inflammation, and stress responses.

GID4 has also been shown to be involved in the regulation of cellular interactions with the immune system. For example, GID4 has been shown to play a role in the regulation of T cell development and function, as well as the regulation of immune cell responses to infection.

In conclusion, GID4 is a gene that has been shown to play a role in a variety of cellular processes that are important for brain development and function, as well as for the regulation of cellular responses to stress and environmental stimuli. Its potential as a drug target or biomarker makes it an attractive target for further study. Further research is needed to fully understand the role of GID4 in cellular processes and to determine its potential as a drug or biomarker.

Protein Name: GID Complex Subunit 4 Homolog

Functions: Substrate-recognition subunit of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1 (Probable) (PubMed:29911972). Binds proteins and peptides with a Pro/N-degron consisting of an unmodified N-terminal Pro followed by a small residue, and has the highest affinity for the peptide Pro-Gly-Leu-Trp (PubMed:29632410). Binds peptides with an N-terminal sequence of the type Pro-[Ala,Gly]-[Leu,Met,Gln,Ser,Tyr]-[Glu,Gly,His,Ser,Val,Trp,Tyr]. Does not bind peptides with an acetylated N-terminal Pro residue (PubMed:29632410)

The "GID4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GID4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets